Hypertension: possible differential risk for blacks in Beta-Blocker Heart Attack Trial (BHAT).

Abstract

Previously reported data document that efficacy of beta-adrenergic antagonists in lowering mortality rates after acute myocardial infarction. Similarly, the higher observed mortality rates among blacks in the Beta-Blocker Heart Attack Trial (BHAT) have been addressed. In this report, we further emphasize the apparent role of prior high blood pressure in the high risk profile of black patients radomized in the BHAT and the similarity in response to therapy to other high risk patients in this study.

• Authors: L J Haywood
• Journal: American journal of hypertension (Am J Hypertens) Vol. 2 Issue 11 Pt 1 Pg. 865-8 (Nov 1989) ISSN: 0895-7061 [Print] United States
• PMID: 2574045 (Publication Type: Clinical Trial, Journal Article, Multicenter Study, Randomized Controlled Trial)

Chemical References

• Adrenergic beta-Antagonists

Topics

• Adrenergic beta-Antagonists (therapeutic use)
• Black People
• Humans
• Hypertension (epidemiology)
• Multicenter Studies as Topic
• Myocardial Infarction (mortality, prevention & control)
• Prospective Studies
• Randomized Controlled Trials as Topic
• Risk Factors